ExeVir ready for clinic with variant-targeting llama antibodyLast year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – Share XExeVir ready for clinic with variant-targeting llama antibodyhttps://pharmaphorum.com/news/exevirs-ready-for-clinic-with-covid-variant-busting-llama-antibody/
Can llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find outBelgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after Share XCan llama antibodies beat COVID-19? Belgium’s ExeVir raises 23m euros to find outhttps://pharmaphorum.com/news/can-llama-antibodies-beat-covid-19-belgiums-exevir-raises-23m-euros-to-find-out/
